We followed our initial genome-wide association study (GWAS) of 527,869 SNPs on 1,172 individuals with prostate cancer and 1,157 controls of European origin-nested in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial prospective study-by testing 26,958 SNPs in four independent studies (total of 3,941 cases and 3,964 controls). In the combined joint analysis, we confirmed three previously reported loci (two independent SNPs at 8q24 and one in HNF1B (formerly known as TCF2 on 17q); P o 10 À10 ). In addition, loci on chromosomes 7, 10 (two loci) and 11 were highly significant (between P o 7.31 Â 10 À13 and P o 2.14 Â 10 À6 ). Loci on chromosome 10 include MSMB, which encodes b-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer. Of the nine loci that showed highly suggestive associations (P o 2.5 Â 10 À5 ), four best fit a recessive model and included candidate susceptibility genes: CPNE3, IL16 and CDH13. Our findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals.
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In developed countries, prostate cancer is the most common noncutaneous malignancy in men 1 . The only established risk factors are age, African ancestry, and a positive family history of disease 1 . Twin studies and epidemiologic observations have suggested a substantial genetic contribution to disease risk 2 . Recently, linkage, admixture mapping and genome-wide studies have identified variants with moderate effects on prostate cancer risk at multiple loci in the 8q24 region [3] [4] [5] [6] [7] , two of which have been replicated by independent groups, and in HNF1B (formerly TCF2) 8 . These loci account for a fraction of the elevated risk for relatives of individuals with prostate cancer, suggesting that additional loci exist 9 . Recognizing the limitations of both candidate gene and linkage studies in identifying common susceptibility genes in prostate cancer, we conducted a two-stage GWAS in order to search for common variants with moderate risk. For the first stage of our cost-effective approach 10 , we used 527,869 SNPs, monitoring 91% of common autosomal SNPs in HapMapII typed from data on the population of European ancestry (CEU; r 2 ¼ 0.8, minor allele frequency (MAF) 45%) 7, 11 . For the second step, we analyzed the most promising 27,326 SNPs from the first scan in 3,941 cases and 3,964 controls. The large number of SNPs genotyped in the second stage enabled us to follow up on regions with moderate association in the initial genome-wide scan (P o 0.068).
We conducted the initial genome-wide scan in a nested casecontrol study of 1,172 prostate-specific antigen (PSA) screened cases (oversampled for aggressive cases; 484 nonaggressive prostate cancer (Gleason score o7 and disease stage oIII) and 688 aggressive prostate cancer (Gleason score Z7 and/or disease stage ZIII)) and 1,157 PSAscreened controls in men of European ancestry from the PLCO Cancer Screening Trial 12, 13 . In the second stage, we successfully genotyped 26,958 SNPs in four additional replication studies totaling 4,020 cases and 4,028 controls (American Cancer Society Cancer Prevention Study II 14 , 1,790/1,797; the Health Professionals Follow-up Study 15 , 619/620; CeRePP French Prostate Case-Control Study 16 , 671/671; and Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 17 , 940/ 940) (Supplementary Methods online). Of the 26,613 SNPs chosen on the basis of the initial genome-wide scan for attempted replication (see below), 24,748 SNPs were of sufficient quality and frequency for analysis in four follow-up studies in men of European background. Initially, we had selected 25,265 SNPs in a second stage from the whole-genome scan on the basis of a P value reflecting an age, center, and population stratification-adjusted polytomous/multinomial regression analysis (4 degree-of-freedom (d.f) test) that accounted for both heterozygous and homozygous variant genotypes and the two groups of cases (nonaggressive and aggressive) in PLCO. We excluded SNPs with higher P values that were in strong linkage disequilibrium (r 2 4 0.8) with a previously selected SNP. The threshold for single SNP selection was P o 0.068. An additional 1,348 SNPs had been selected on the basis of a 2-SNP test that improved the P value relative to the single-SNP statistic by at least an order of magnitude. Furthermore, 1,508 SNPs had been chosen to monitor population stratification. These SNPs detected comparable first principal components as a set of 10,693 SNPs drawn from the second stage (described above) which had been selected because they had little evidence for linkage disequilibrium over 200 kb (r 2 o 0.0075) (Supplementary Methods) 18 .
The 26,958 SNPs reliably genotyped in the second stage covered 7,608 distinct chromosomal regions defined by a maximal distance between two SNPs of less than 100 kb. We found that 2,853 regions contained only one SNP, and 501 regions contained 10 or more SNPs.
(Supplementary Methods and Supplementary Table 1 online). Of these regions, we followed up on 150 that had at least one SNP with an observed P value o10 À3 (Fig. 1) . SNPs with a P value 410 À3 in the combined analysis of our two stages are unlikely to reach convincing genome-wide significance in a combined analysis including an additional large third stage-effectively doubling the overall number of cases and controls of the study-as is planned in the next stage of Cancer Genetic Markers of Susceptibility (CGEMS) follow-up (see Supplementary Methods). The largest region on 8q24 (between position 127.4 Mb and 128.9 Mb) contained 28 SNPs with P values o10 À3 , but this region was deliberately explored with 192 SNPs drawn from the initial genome scan on the basis of strong prior evidence for associations with breast, colon and prostate cancer 7, 19, 20 . An additional 21 regions contained two or more significant SNPs. A remaining 115 significant SNPs were each located in a different region, a possible consequence of the filtering procedure based on linkage disequilibrium (see Supplementary Methods). Of note, almost one-fifth of the candidate regions identified were located on chromosomes 5 and 10, which may harbor multiple susceptibility loci for prostate cancer.
Our two-stage GWAS in prostate cancer has identified two sets of SNPs: one comprises established and newly identified loci associated with prostate cancer risk, and the second includes SNPs with P o 10 À3 that merit additional follow-up studies 18 . Most of the SNPs that achieved or approached genome-wide significance in the follow-up studies were not ranked in the top 1,000 SNPs in the initial genomewide scan (Table 1) . Indeed, the four most significant newly identified SNPs ranked 319 (CTBP2), 2,439 (chromosome 11), 24,223 (MSMB) and 24,407 (JAZF1), respectively, in the initial scan. Thus, these results support the value of genotyping a large number of SNPs in follow-up studies. Genotype counts for each SNP in each of the three phenotype groups (controls, nonaggressive cases and aggressive cases) are freely available as computed association statistics. Individual genotype data in the initial GWAS study are available for registered users through the CGEMS portal, thus providing investigators with an opportunity for additional analyses.
The results of our combined joint analysis by polytomous/multinomial logistic regression of the initial genome-wide scan and the four follow-up studies provide the necessary independent replication of an association with a common genetic variation in HNF1B ( Table 1 and  Supplementary Tables 2-7 online) 8 . We confirmed two independent loci in 8q24 previously associated with prostate cancer in a population of European origin but did not find associations for three SNPs in this region related to prostate cancer risk in men of other ancestral origin 6 ; namely, rs7000448, rs6983561 and rs13254738. The P value of a second SNP, rs4242382, in strong linkage disequilibrum (LD) with the previously reported rs1447295 was nearly an order of magnitude smaller than that of rs1447295 (refs. 3-7). Several newly identified loci met or approached the 'standard of genome-wide significance' , P o 10 À7 . These include four loci on chromosomes 7, 10 (two loci) and 11 that are highly significant (P o 2.14 Â 10 À6 ); moreover, the three loci on chromosomes 7 and 10 include candidate susceptibility genes, CTBP2, MSMB and JAZF1. Furthermore, rs10896449 lies on the long arm of chromosome 11 and is located 67 kb upstream of a gene overexpressed in myeloma, MYEOV 21 . Of note, we observed lower P values when we analyzed aggressive and nonaggressive tumors together with a 1-d.f. trend test: rs10486567 in JAZF1 showed association with P ¼ 1.2 Â 10 À7 , and rs4962416 in CTBP2 showed association with P ¼ 2.7 Â 10 À8 . rs10993994, the SNP with the lowest P value among those in the newly identified loci, resides in the proximal promoter of MSMB (Fig. 2) and functionally alters in vitro gene expression 22 . MSMB encodes MSP, a 10.7-kDa nonglycosylated cysteine-rich protein that is a member of the immunoglobulin binding factor family synthesized by epithelial cells in the prostate and secreted into seminal plasma. MSP and its binding protein in serum, PSPBP, are potential serum markers for early detection of high-grade prostate cancer 23, 24 . Although its expression has been noted in normal and neoplastic prostate tissue, MSMB can be silenced by EZH2 in advanced, androgen-insensitive prostate cancer 25 . Thus, variants in MSMB may predispose to prostate cancer through altered gene expression.
To determine whether additional, putative functional variants in MSMB are in strong LD with rs10993994, we conducted bidirectional sequence analysis across the gene region in 90 HapMap CEU individuals and in 40 men with aggressive phenotype and 40 controls from the PLCO prostate cancer study ( Supplementary Fig. 1 online) . We identified a nonsynonymous variation in the initiation codon (ATG to ATA, altering Met to Ile) in a single CEU individual. We did not observe any other potentially functional variants. The probability that a SNP (with a MAF B40%) in perfect linkage disequilibrium with rs10993994 might have escaped detection in the resequenced regions is remote (P o 10 À60 ).
Our two-stage GWAS identified six SNPs in a region on chromosome 10 that harbors two candidate genes, CTBP2 and ZRANB1 ( Supplementary Fig. 2 online) . The strongest signal was observed for rs4962416 in the fifth intron of CTBP2 (P ¼ 1.70 Â 10 À7 ), which encodes a member of the C-terminal binding protein (CTBP) family The result of the trichotomous (nonaggressive and aggressive disease distinguished) logistic regression of the combined genotypes generated in the initial PLCO study and the four follow-up studies-adjusted for age in ten-year intervals, study/study center and four eigenvectors to control population stratification-is shown for the SNP providing the strongest signal in each region 10 . Included are the individual ranks and P values observed for the same SNP in the primary genome-wide scan in PLCO using a trichotomous regression analysis adjusted for the age in five years, study/center and three eigenvectors to control population stratification in an incident density sampling strategy. For five of the regions, additional SNPs were typed and reached P value o 2.14 Â 10 À6 : for rs4242382 (rs4242384, rs1447295, rs7837688, rs11988857, rs7017300 and rs9656816), for rs6983267 (rs10505477, rs7837328 and rs7014346), for rs4430796 (rs7501939), for rs10993994 (rs11006207) and for rs4962416 (rs11245446, rs7077275 and rs4962708); see Supplementary Tables 1 and 2 
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known to be transcriptional corepressors activated under metabolic stress. CTBP2 is highly expressed in prostate tissue, and its expression has been associated with decreased PTEN expression and activation of the phosphatidylinositol 3-kinase pathway 26 . We confirmed rs10486567 in the second intron of the JAZF zinc finger 1 gene, JAZF1, located on chromosome 7 (P ¼ 2.14 Â 10 À6 ). JAZF1 encodes a three C2-H2-type zinc finger protein that is a transcriptional repressor of NR2C2, a nuclear orphan receptor that is highly expressed in prostate tissue and that reportedly interacts with the androgen receptor. JAZF1 is a component of a fusion gene with SUZ12 (also known as JJAZ1) found in endometrial stromal tumors 27 .
This strategy-analyzing two phenotypes of prostate cancer, aggressive and nonaggressive-combined with genotype-based statistics rather than a trend statistic yielded strong associations that might have been missed using standard approaches. We found 13 loci that have at least one SNP with P o 5 Â 10 À5 (Supplementary Table 2) . Of these SNPs, three are located within or in proximity of possible candidate genes-IL16, CDH13 and CPNE3-whose associations with disease risk are best described using a recessive model for the at-risk allele yet do not meet this threshold under a trend model. Two SNPs are notable because they seem to be associated primarily with aggressive disease. In IL16, the lowest P value is observed for rs4072111, a nonsynonymous SNP that shifts serine to proline (Grantham score of 74) in the twelfth exon of this lymphocyte chemoattractant factor gene. The aminoacid change resides in the C terminus, shown to modulate T-cell activation, whereas the N terminus regulates cell cycle. Variation in gene expression of IL16 has been associated with alleles including rs7179134, rs7180245 and rs11637363, but none of these SNPs showed association with prostate cancer in our initial GWAS (P 4 0.66) 28 . Through analysis of the LD pattern of IL16, we found that the at-risk proline variant is carried by a haplotype associated with high expression. A SNP located in intron 1 of CDH13 is also of note because of the observed reduction in transcript levels of CDH13 in human prostate cancer cell lines and tissue samples: in vitro, increased expression of CDH13 in DU145 cells inhibits tumorigenesis, whereas its silencing in BPH1 cells facilitates tumorigenesis 29 . The SNP with the lowest P value (P ¼ 1.26 Â 10 À5 ) near CPNE3, a member of the calciumdependent membrane-binding proteins known to aggregate phosphatidylserine membranes in a calcium-dependent manner, is located 7 kb downstream of its transcript. This SNP, rs4961199, is associated with altered expression of CPNE3 in lymphoblastoid cell lines (http://www.sph.umich.edu/csg/liang/asthma/).
We observed a notable P value (1.01 Â 10 À5 ) for rs12771728 on chromosome 10, chosen on the basis of a 2-SNP analysis, which suggested an augmented signal relative to the primary SNP, rs6586085, chosen in the 1-SNP model (P ¼ 0.00488) in the genome-wide scan (Supplementary Methods). rs12771728 and rs6586085 reside near MINPP1, a gene encoding a phosphatase with similarity to PTEN. MINPP1 has been proposed to be a low-penetrant susceptibility allele in malignant follicular thyroid tumors 30 . However, in the joint analysis, the P value for rs6586085 alone was 0.3, and the 2-SNP analysis with rs12771728 did not improve upon this P value. Further investigation is required, as this association has not been formally replicated 18 . Table 1 were used to infer the distribution of odds ratios for prostate cancer risk in the European population assuming a multiplicative multilocus odds ratio model across the seven independent risk markers. An odds ratio of 1 (log 10 OR ¼ 0) corresponds to the median risk in the population. With a total of 2,187 different seven-locus genotypes combinations, odds ratios vary over a roughly fourfold range (OR ¼ 0.5-2.0; log 10 OR ¼ -0.3 -0.3), with extreme categories showing greater but more imprecise risk differentials. The validity of the multiplicative model cannot be assessed, and estimates of single-locus odd ratios from the initial scans that identified the loci are likely to be exaggerated.
Of the two independent 8q24 markers (rs4242382 and rs6983267) and five SNP markers outside of 8q24 with P r 2.14 Â 10 À6 in the polytomous analysis, all remained strongly associated (P r 3.24 Â 10 À7 ) with risk of prostate cancer after mutual adjustment for the other SNP markers (Supplementary Table 8 online). As there is little evidence for multiple functional variants in a single region, we examined possible interactions between regions with a single SNP per region. There was no compelling evidence that the interactions of the seven independent risk markers departed from a multiplicative model on the odds ratio scale (the minimum P value among the 7 C 2 ¼ 21 tests for adding pairwise interaction terms to the joint model was P ¼ 0.01). The odds ratio comparing the men at low risk (corresponding to 10th percentile for risk) to those at high risk (corresponding to 90th percentile for risk) was 2.70 (Fig. 3, dashed lines) . Although genotypes at these seven loci may identify men at substantially increased or decreased risk of prostate cancer, most men are expected to fall into intermediate risk categories.
Individual population attributable risks (PARs) for prostate cancer for each of the seven independent loci ranged from 8% to 20% (Fig. 3 and Supplementary Table 9 online). Although the total PAR from multiple loci is always less than the sum of the individual PARs, considered together, the seven loci contribute to a substantial though yet-to-be-defined fraction of prostate cancer incidence in populations of European ancestry. Our data provide a foundation for determining the cumulative risk of moderate-to low-penetrance alleles for prostate cancer and suggest that further investigation should identify additional loci. In this regard, the alleles identified to date do not fully capture the complex contribution of genetic factors to prostate cancer incidence. For at least one of these genes, MSMB, the strongest signal associated with prostate cancer (rs10993994) is known to be functionally active; thus, its corresponding polymorphism is a plausible causal variant. For the other loci, a search for candidate causal variants should be conducted 18, 22 . The robust evidence for multiple associations presented in this study identifies genes that may elucidate the etiologic pathways contributing to the development of prostate cancer. The multiple loci reported here as well as additional loci that are likely to be identified in follow-up of this and other studies will sharpen estimates of the increased risk of prostate cancer associated with these genetic loci along an almost continuous scale.
METHODS
Analytical plan. The primary follow-up analysis explored the association between single SNPs and prostate cancer susceptibility. Briefly, 25,265 SNPs were selected on the basis of single-SNP association tests in the previously reported GWAS in PLCO (1,172 PSA-screened cases oversampled for aggressive disease and 1,157 PSC-screened controls in men of European background). An additional 1,348 SNPs were selected on the basis of two-SNP association tests, and 897 SNPs were chosen to explore high-profile candidate genes, finemapping of 8q24, and other non-CGEMS hypotheses. Another 1,508 SNPs were chosen to assess population structure. To maximize the number of regions that could be explored, we applied a filter based on linkage disequilibrium such that we excluded SNPs for which there was a more significant result observed with a separate SNP with an r 2 Z 0.8.
For the follow-up replication studies, all one-and two-SNPs analyses were conducted using unconditional polytomous logistic regression, adjusted for age (in ten-year categories), study, and center for the two studies for which this information was available. Four continuous covariates were included to account for population stratification based on principal components analysis of genotype correlations. Analysis was carried out in three ways: for each study separately, for the pooled replication studies (all except PLCO), and for all studies combined. Genotype effects were modeled individually, and a score test with two d.f. for each case phenotype was computed (separate effects for aggressive and nonaggressive cases result in a 4-d.f. test).
Replication samples. In the second stage, we genotyped 26,958 SNPs in four follow-up studies of men of European background totaling 4,020 cases and 4,028 controls drawn from the American Cancer Society Cancer Prevention Study II 14 , the Health Professionals Follow-up Study 15 , CeRePP French Prostate Case-Control Study 16 , and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 17 . These studies were approved by the appropriate institutional review boards.
Replication genotyping. We genotyped 8,693 samples (including study duplicates) passing sample handling quality-control metrics in the Core Genotyping Facility of the National Cancer Institute using a custom-designed iSelect Infinium assay (Illumina) with content described above. Using quality-control measures, we removed samples with call rates under 90% and SNPs with call rates under 95%. Fitness for Hardy-Weinberg proportion was assessed for each SNP in control subjects by study but not used to exclude SNP assays. Genotyping was attempted twice in 141 (1.6%) of samples.
A small fraction of subjects who were successfully genotyped were excluded from analysis because they: (i) were unanticipated interstudy and intrastudy duplicates; (ii) showed unanticipated African and/or Asian admixture with o85% European ancestry; (iii) belonged to sparse groups (namely, two PLCO subjects who were the only participants from one study center, and five nonaggressive cases from the portion of the CPS-II study that provided only buccal DNA); and/or (iv) had incomplete covariate data.
In the iSelect assay, a total of 525 discordant genotypes were detected out of 9,050,673 genotype comparisons (332 duplicate DNA pairs) yielding a total discordance rate of 6 Â 10 -5 ; the lowest rate of concordance for individual SNP assays was 98.3% for the study with buccal samples and 98.9% for the study with blood samples. Infinium genotype cluster plots for notable SNPs are included in Supplementary Methods. For the seven loci with the lowest associated P values (three known and four newly identified), we validated genotype calls determined by the iSelect Infinium assay by TaqMan (ABI) assay in two studies, HPFS and CPS-II (buccal DNA component) 18 .
Informatics. We used GLU (Genotyping Library and Utilities), a new suite of tools that is being released as an open-source application, to manage, archive and analyze the genome-wide association data. We used the STRUCTURE and EIGENSTRAT programs to assess population heterogeneity (see URLs section below).
URLs. GLU, http://cgf.nci.nih.gov/development/tooldev.html; STRUCTURE, http://pritch.bsd.uchicago.edu/structure.html; EIGENSTRAT, http://genepath. med.harvard.edu/~reich/EIGENSTRAT.htm; Tagzilla, http://tagzilla.nci.nih. gov; CGEMS portal, http://cgems.cancer.gov/data.
Note: Supplementary information is available on the Nature Genetics website.
